By Battle Road Research, an equity research firm.
Most people encounter a Victorian process when donating blood. They have a vein opened, allowing their blood to drip through tubing into a bag, which is stored in a cooler for transport. Even though blood traditionally has been collected "whole" like this, it is rarely given to patients in whole form.
But Braintree, Mass-based Haemonetics, with annual revenue of about $600 million and a market cap of $1.4 billion, manufactures devices that collect different blood components separately.As you probably know, blood is composed of a few important important components: plasma (a straw-colored medium for the other components), red blood cells (which deliver oxygen) and platelets (for clotting). A fourth component, white blood cells, is important to the body's immune system, but it cannot be donated from one person to another. Of the three main components that can be transferred from donor to patient, plasma has yielded the most revenue for Haemonetics. As a method of ensuring recurring revenue from its devices and eliminating high capital costs, Haemonetics will often place its equipment at blood banks or other collection centers and generate revenue from disposable products utilized in the devices. Haemonetics' vertical integration across all facets of blood management is unique. The company manufactures a wide variety of products that aid in putting blood back into hospital patients. For example, the company has a product called OrthoPAT, which collects blood lost during and after orthopedic surgeries, cleans it, and transfuses it back into the patient. This reduces the need for donor blood for these operations, conserving it for trauma and other high-use needs.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV